Fulcrum Therapeutics (FULC) News Today $6.47 -0.18 (-2.65%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FULC Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Maxion Therapeutics Strengthens Board with Appointment of Dr. Santiago Arroyo as a Non-Executive DirectorAugust 27 at 4:46 PM | markets.businessinsider.comFulcrum Therapeutics to Present at Upcoming Investor Conferences in September 2025August 26 at 8:31 AM | quiverquant.comQFulcrum Therapeutics to Present at Upcoming Investor MeetingsAugust 26 at 8:00 AM | globenewswire.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 24, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by AnalystsAugust 22, 2025 | americanbankingnews.comFulcrum Therapeutics, Inc. $FULC Shares Sold by Connor Clark & Lunn Investment Management Ltd.August 20, 2025 | marketbeat.comXTX Topco Ltd Takes Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)August 15, 2025 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street ZenAugust 10, 2025 | marketbeat.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2025 | globenewswire.comAIRNA Appoints Tamara Joseph as Chief Legal Officer and Kristina Storey as Head of Regulatory AffairsAugust 6, 2025 | finance.yahoo.comFULC Fulcrum Therapeutics, Inc. - Seeking AlphaAugust 5, 2025 | seekingalpha.comFY2025 EPS Estimates for FULC Raised by Cantor FitzgeraldAugust 2, 2025 | marketbeat.comHC Wainwright Issues Optimistic Outlook for FULC EarningsAugust 2, 2025 | marketbeat.comLeerink Partnrs Has Negative Forecast for FULC Q3 EarningsAugust 2, 2025 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Stock Price Expected to Rise, Royal Bank Of Canada Analyst SaysJuly 31, 2025 | marketbeat.comFulcrum Therapeutics upgraded to Buy from Neutral at H.C. WainwrightJuly 30, 2025 | msn.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded at HC WainwrightJuly 30, 2025 | marketbeat.comFulcrum Therapeutics shares slide 17% after sickle cell trial resultsJuly 29, 2025 | msn.comFulcrum reports data from sickle cell disease trial, posts Q2 resultsJuly 29, 2025 | msn.comFulcrum Therapeutics stock falls after sickle cell disease trial resultsJuly 29, 2025 | investing.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025July 29, 2025 | globenewswire.comFulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell DiseaseJuly 29, 2025 | globenewswire.comFulcrum Therapeutics stock soars ahead of sickle cell trial dataJuly 29, 2025 | za.investing.comFulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell DiseaseJuly 28, 2025 | globenewswire.comFulcrum Therapeutics, Inc. (FULC) Latest Press Releases & Corporate ...July 25, 2025 | finance.yahoo.comFulcrum Therapeutics (FULC) Projected to Post Earnings on WednesdayJuly 23, 2025 | marketbeat.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing ...July 12, 2025 | morningstar.comMFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 | globenewswire.comFulcrum Therapeutics (NASDAQ:FULC) investors are sitting on a loss of 60% if they invested five years agoJune 28, 2025 | finance.yahoo.comFulcrum Therapeutics Inc. Annual Cash Flow Statement - MarketWatchJune 25, 2025 | marketwatch.comCantor Fitzgerald Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC)June 22, 2025 | theglobeandmail.comResearch Analysts Set Expectations for FULC FY2026 EarningsJune 11, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Millennium Management LLCJune 11, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Two Sigma Investments LPJune 8, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 8, 2025 | marketbeat.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comMackenzie Financial Corp Has $555,000 Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)June 3, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest UpdateJune 2, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 38,600 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)May 31, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (FULC): A Bull Case TheoryMay 30, 2025 | msn.comFulcrum Therapeutics to Present at Upcoming Medical MeetingsMay 29, 2025 | globenewswire.comFulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 29, 2025 | globenewswire.comLeerink raises Fulcrum Therapeutics stock to OutperformMay 26, 2025 | uk.investing.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded by Leerink Partnrs to "Strong-Buy" RatingMay 26, 2025 | marketbeat.comWoodline Partners LP Increases Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)May 26, 2025 | marketbeat.comNorthern Trust Corp Buys 142,578 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)May 26, 2025 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded to Outperform at Leerink PartnersMay 25, 2025 | marketbeat.comLeerink Partners Upgrades Fulcrum Therapeutics (FULC)May 23, 2025 | msn.comFulcrum gains as Leerink upgrades ahead of data for lead assetMay 23, 2025 | msn.comSherbrooke Park Advisers LLC Has $212,000 Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)May 23, 2025 | marketbeat.com Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FULC Media Mentions By Week FULC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FULC News Sentiment▼1.021.03▲Average Medical News Sentiment FULC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FULC Articles This Week▼53▲FULC Articles Average Week Get the Latest News and Ratings for FULC and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Fulcrum Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AVDL News Today ARDX News Today JANX News Today HROW News Today VERA News Today AMPH News Today SNDX News Today ETNB News Today COGT News Today SPRY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FULC) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access